CLBX — Cellbxhealth Share News
0.000.00%
Last trade - 00:00- £9.40m
- £7.84m
- £1.35m
Issue of LTIP Options and Share Options
Results of Eisai Phase 2 pilot study
Novel findings using Parsortix
Berenberg predicts 'another eventful year' for MedTech sector
Analysis of CTC-DNA and ctDNA using Illumina assay
Parsortix used in research paper from ETH Zurich
Europe Research Roundup: Anglo American , Energean, Savills
Brief: Angle Expects Rev For 2024 To Be Up 31%
Brief: Angle FY Net Income GBP -14 Million
Trading Update
HER2 presentation at SABCS
Research on HER2 assay kit showcased at AACR
Parsortix based PD-L1 assay showcased at AACR
ANGLE presents two posters at EACR
Parsortix enriched CTC & ctDNA in NSCLC patients
Publication demonstrates CTC profiling potential
Brief: Angle Plc Sees Revenues For H2 To Double Compared To H1
Brief: Angle H1 Pretax Profit GBP -8.256 Mln
100th publication supporting Parsortix system use